Efficacy of Clostridium butyricum preparation concomitantly with Helicobacter pylori eradication therapy in relation to changes in the intestinal microbiota

Microbiology and Immunology

Volumn 52, Issue 3, 2008, Pages 156-161

  Imase, Kyoto ^a   Takahashi, Motomichi ^a,b   Tanaka, Akifumi ^a   Tokunaga, Kengo ^a   Sugano, Hajime ^a   Tanaka, Mamoru ^b   Ishida, Hitoshi ^a   Kamiya, Shigeru ^a   Takahashi, Shin'ichi ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Miyarisan Pharmaceutical Co   (Japan)

Author keywords

C. butyricum MIYAIRI588; C. difficile; H. Pylori eradication therapy; Intestinal microbiota

Indexed keywords

AMOXICILLIN; CBM 588; CLARITHROMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CMB 588; LANSOPRAZOLE; PROBIOTIC AGENT; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; ENTEROTOXIN; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE;

ADULT; AGED; ANAEROBE; ARTICLE; BACTERIAL COUNT; BACTERIUM DETECTION; BIFIDOBACTERIUM; CLINICAL ARTICLE; CLOSTRIDIUM BUTYRICUM; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; GASTRODUODENAL ULCER; HELICOBACTER PYLORI; HUMAN; INTESTINE FLORA; MALE; NONHUMAN; CHEMISTRY; FECES; GASTROINTESTINAL TRACT; GROWTH, DEVELOPMENT AND AGING; HELICOBACTER INFECTION; MICROBIOLOGY; MIDDLE AGED; PEPTIC ULCER;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM BUTYRICUM; CLOSTRIDIUM DIFFICILE; HELICOBACTER PYLORI;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; CLOSTRIDIUM BUTYRICUM; COLONY COUNT, MICROBIAL; DIARRHEA; ENTEROTOXINS; FECES; FEMALE; GASTROINTESTINAL TRACT; HELICOBACTER INFECTIONS; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER; PROBIOTICS;

EID: 51449123258     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2008.00026.x     Document Type: Article

References (32)

1. The European Helicobacter pylori Study Group. (1997) Current European concepts in management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 41: 8-13.
2. van Amsterdam K., van Vliet A.H.M., Kusters J.G., van der Ende A. (2005) Of microbe and man: determinants of Helicobacter pylori-related diseases. FEMS Microbiol Rev 30: 131-56.
3. Asaka M., Sugiyama T., Kato M., Satoh K., Kuwayama H., Fukuda Y., Fujioka T., Takemoto T., Kimura K., Shimoyama T., Shimizu K., Kobayashi S. (2001) A multicenter, double blind study on the triple therapy with lansoprazole / amoxicillin / clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 6: 254-61.
4. MiwaH., Okura R., Murai T., Sato K.,Nagahara A., Hirai S., Watanabe S., Sato N. (1999) Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 13: 741-6.
5. D'Souza A.L., Rajkumar C., Cooke J., Bulpitt C.J. (2002) Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 324: 1361.
6. McFarland L.V. (2006) Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 101: 812-22.
7. Seki H., Shiohara M., Matsumura T., Miyagawa N., Tanaka M., Komiyama A., Kurata S. (2003) Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatr Intern 45: 86-90.
8. Sato R., Tanaka M. (1997) Intestinal distribution and intraluminal localization of orally administered Clostridium butyricum in rats. Microbiol Immunol 41: 665-71.
9. Mitsuoka T. (2002) Research in intestinal flora and functional foods. J Intestinal Microbiol 15: 57-89.
10. O'Connor D., Hynes P., Cormican M., Collins E., Corbett-Feeney G., Cassidy M. (2001) Evaluation of methods for detection of toxins in specimens of feces submitted for diagnosis of Clostridium difficile- associated diarrhea. J ClinMicrobiol 39: 2846-9.
11. Ables A., Z., Simon I., Melton E.R. (2007) Update on Helicobacter pylori treatment. Am Fam Physician 75: 351-8.
12. Bartlett J.G. (2002) Antibiotic-associated diarrhea. N Engl J Med 346: 334-9.
13. Buhling A., Radun D., MullerW.A., Malfertheiner P. (2001) Influence of anti-Helicobacter triple therapy with metronidazole, omeprazile and clarithromycin on intestinal microflora. Aliment Pharmacol Ther 15: 1445-52.
14. Pothoulakis C., LaMont J.T. (1993) Clostridium difficile colitis and diarrhea. Gastroenterol Clin North Am 22: 623-37.
15. Kamiya S., Taguchi H., Yamaguchi H., Osaki T., Takahashi M., Nakamura S. (1997) Bacterioprophylaxis using Clostridium butyricum for lethal caecitis by Clostridium difficile. Rev Med Miclobiol 8: S57-S59.
16. Takahashi M., Taguchi H., Yamaguchi H., Osaki T., Kamiya S. (2000) Studies of the effect of Clostridium butyricum on Helicobacter pylori in several test models including gnotobiotic mice. J MedMicrobiol 49: 635-42.
17. Takahashi M., Taguchi H., Yamaguchi H., Osaki T., Komatsu A., Kamiya S. (2004) The effect of probiotic treatment with Clostridium butyricum on enterohemorrhagic Escherichia coli O157: H7 infection in mice. FEMS Immnol Med Microbiol 41: 219-26.
18. Ichikawa H., Kuroiwa T., Inagaki A., Shineha R., Nishihira T., Satomi S., Sakata T. (1999) Probiotic bacteria stimulate gut epithelial cell proliferation in rat. Dig Dis Sci 44: 2119-23.
19. Okamoto T., Sasaki M., Tsujikawa T., Fujiyama Y., Bamba T., Kusunoki M. (2000) Preventive efficacy of butyrate enemas and oral administration of Clostridium butyricum M588 in dextran sodium sulfate-induced colitis in rats. J Gastroenterol 35: 341-6.
20. RoedigerW.E., Moore A. (1981) Effect of short-chain fatty acid on sodium absorption in isolated human colon perfused through the vascular bed. Dig Dis Sci 26: 100-6.
21. Nakaya R., Chida T. (1985) Antibiotics and intestinal bacterial flora. Biomedicine Ther 14: 598-604.
22. Ducluzeau R., LadireM., Callut C., Raibaud P., Abrams G.D. (1977) Antagonistic effect of extremely oxygen sensitive clostridia from the microflora of conventional mice and of Escherichia coli against Shigella flexneri in the digestive tract of gnotobiotic mice. Infect Immun 17: 415-24.
23. Tazume S., Ozawa A., Yamamoto T., Takahashi Y., Takeshi K., Saidi S.M. (1993) Ecological study on the intestinal bacteria flora of patients with diarrhea. Clin Infect Dis 16: S77-S82.
24. Clausen M.R., Bonnen H., Tvede M., Mortensen P.B. (1991) Colonic fermentation to short-chain fatty acids is decreased in antibiotic-associated diarrhea. Gastroenterol 101: 1497-504.
25. Tanaka M., Miyagawa N., Tsutsumi Y. (2000) Preventive effect of Clostridium butyricum on the side effect of the Helicobacter pylori eradication. Chin J Gastroenterol 5: A116.
26. McFarland L.V., Mulligan M.E., Kwokry Y.Y. (1998) Nosocomial acquisition of Clostridium difficile infection.N. Engl. J. Med. 320: 204-10.
27. Oldfield E.C. (2004) Clostridium difficile-associated diarrhea: risk factors, diagnostic methods, and treatment. Rev Gastroenterol Disord 4: 186-95.
28. Settle C.D.,Wilcox M.H. (1996) Antibiotic-induced Clostridium difficile infection. Aliment Pharmacol Ther 10: 835-41.
29. Nawaz A., Mohammed I., Ahsan K., Kurakurum A., Hadjiyane C., Pellecchia C. (1998) Clostridium difficile colitis associated with treatment of Helicobacter pylori infection. Am J Gastoroenterol 93: 1175-6.
30. Kuroiwa T., Kobari K., Iwanaga M. (1990) Inhibition of enteropathogens by Clostridium butyricum MIYAIRI 588. J Jpn Assoc Infect Dis 64: 257-63.
31. Servin A.L. (2004) Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev 28: 405-40.
32. Gerrits M.M., van Vliet A.H., Kuipers E.J., Kusters J.G. (2006) Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis 6: 699-709.